Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about GLUE, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| GSPT1 MGD MRT-2359 | Castration-Resistant Prostate Cancer (CRPC) | Phase 2 · NCT07745361 | Recruiting |
| MRT-6160 | Healthy Volunteers | Phase 1 · NCT06597799 | Completed |
| MRT-8102 | Healthy Volunteers | Phase 1 · NCT07119125 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not GLUE's own candidates): Temozolomide, Apalutamide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
GLUE holds $577.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $42.5M/quarter from operations, an estimated runway of 40.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 39 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GLUE files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Baker Bros. Advisors LP | Institution (13G, 5%+) | 8,876,346 | 10.39% | 2026-03-31 |
| T. Rowe Price Associates, Inc. | Institution (13G, 5%+) | 7,356,865 | 8.61% | 2026-09-30 |
| Blackrock Inc. | Institution (13F) | 7,192,446 | 8.42% | 2026-09-30 |
| Vestal Point Capital, LP | Institution (13G, 5%+) | 7,130,000 | 8.34% | 2026-09-30 |
| Ali Behbahani Director · +78,600 options |
Insider | 6,692,298 | 7.83% | 2026-07-01 |
| New Enterprise Associates 17, L.P. | 5%+ holder (13D) | 6,692,298 | 7.83% | 2026-07-01 |
| NEA Management Company, LLC | Institution (13F) | 6,692,298 | 7.83% | 2026-09-30 |
| Adam Goulburn | 5%+ holder (13G) | 6,513,765 | 7.62% | 2026-03-31 |
| Versant Venture Capital VI, L.P. 10% owner |
Insider | 5,652,922 | 6.62% | 2024-10-28 |
| BVF PARTNERS L P/IL | Institution (13G, 5%+) | 4,276,578 | 5.00% | 2026-09-30 |
| BVF Inc. | Institution (13F) | 4,276,578 | 5.00% | 2026-09-30 |
| TCG Crossover Management, LLC | Institution (13F) | 3,781,532 | 4.43% | 2026-09-30 |
Share count 85,450,119 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-10-05 filed 2026-10-06 |
Bowen Matthew |
Sale (S) | 13 | $10.56 | 25,891 |
| 2026-07-16 filed 2026-07-17 |
Warmuth Markus |
Sale (S) | 9,500 | $23.18 | 585,038 |
| 2026-07-15 filed 2026-07-16 |
Champoux Jennifer |
Option exercise (M) | 4,351 | – | – |
| 2026-07-15 filed 2026-07-16 |
Champoux Jennifer |
Option exercise (M) | 4,351 | $3.98 | 66,722 |
| 2026-07-15 filed 2026-07-16 |
Champoux Jennifer |
Sale (S) | 4,351 | $23.38 | 62,371 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GLUE and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →